Michael Pellini, M.D. joined Foundation Medicine (NASDAQ: FMI) as President and Chief Executive Officer in May 2011 and transitioned to Chairman in February 2017. As a physician with more than 20 years of executive experience with companies at the forefront of clinical diagnostics and genomics, Dr. Pellini brings a breadth of understanding in personalized medicine, with an interest and focus in oncology.
He currently serves as a member of the Board of Directors for Tango Therapeutics, Singular Genomics, the Personalized Medicine Coalition, the Mission Hospital Foundation, and Mass BIO, in addition to his Board Chair position with Foundation Medicine. Dr. Pellini is a member of the President’s Leadership Council for the Sydney Kimmel Medical School at Thomas Jefferson University and the Advisory Board for Mission Hospital’s Cancer Institute (Provident/St. Joseph Health).